GP plus adebrelimab vs. chemo alone for nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a specific type of nasopharyngeal cancer (nonkeratinizing).
- Your cancer is at an advanced stage (T4N0-1M0 or T1-4N2-3M0) but has not spread to other parts of the body.
- You have not had any previous cancer treatment.
- You are generally healthy enough for chemotherapy (good organ function, no serious infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation for people with a high-risk type of nasopharyngeal cancer (stage IVA). The goal is to see if this combination helps control the cancer better.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.